

# Clinical trials of ACAT inhibition for cardiovascular prevention in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 ACAT inhibitors

Trial	Treatments	Patients	Trials design and methods
<b>pactimibe vs placebo</b>			
<b>CAPTIVATE , 2009</b> [NCT00151788] n=448/444 follow-up: 15 months (mean)	pactimibe 100mg daily versus placebo	patients with familial hypercholesterolemia and carotid atherosclerosis	Parallel groups double blind United States, Canada, Europe, South Africa, Israel
<b>ACTIVATE , 2006</b> [NCT00185042] n=266/268 follow-up: 18 months	pactimibe 100 mg daily versus placebo	patients with angiographicallydocumented coronary disease	Parallel groups double blind

## References

### CAPTIVATE, 2009:

Meuwese MC, de Groot E, Duivenvoorden R, Trip MD, Ose L, Maritz FJ, Basart DC, Kastelein JJ, Habib R, Davidson MH, Zwinderman AH, Schwocho LR, Stein EA ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA 2009 Mar 18;301:1131-9 [[19293413](https://doi.org/10.1001/jama.301.11.1131)]

### ACTIVATE, 2006:

Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, Davidson MH, Deanfield JE, Wisniewski LM, Hanyok JJ, Kassalow LM Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006 Mar 23;354:1253-63 [[16554527](https://doi.org/10.1056/NEJMoa054699)]

## 2 Inhibition of acyl coenzyme A:cholesterol acyltran

Trial	Treatments	Patients	Trials design and methods
<b>pactimibe vs placebo</b>			
<b>CAPTIVATE , 2009</b> [NCT00151788] n=448/444 follow-up: 15 months (mean)	pactimibe 100mg daily versus placebo	patients with familial hypercholesterolemia and carotid atherosclerosis	Parallel groups double blind United States, Canada, Europe, South Africa, Israel

continued...

Trial	Treatments	Patients	Trials design and methods
<b>ACTIVATE , 2006</b> [NCT00185042] n=266/268 follow-up: 18 months	pactimibe 100 mg daily versus placebo	patients with angiographically documented coronary disease	Parallel groups double blind

## References

### **CAPTIVATE, 2009:**

Meuwese MC, de Groot E, Duivenvoorden R, Trip MD, Ose L, Maritz FJ, Basart DC, Kastelein JJ, Habib R, Davidson MH, Zwinderman AH, Schwocho LR, Stein EA ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. *JAMA* 2009 Mar 18;301:1131-9 [[19293413](#)] [10.1001/jama.301.11.1131](#)

### **ACTIVATE, 2006:**

Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, Davidson MH, Deanfield JE, Wisniewski LM, Hanyok JJ, Kassalow LM Effect of ACAT inhibition on the progression of coronary atherosclerosis. *N Engl J Med* 2006 Mar 23;354:1253-63 [[16554527](#)] [10.1056/NEJMoa054699](#)

## 3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.